Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody

Published:2020-04-08 Issue:10 Volume:34 Page:2708-2721
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Nakamura Kyohei,Casey Mika,Oey Harald,Vari Frank,Stagg John,Gandhi Maher K.,Smyth Mark J.

Funder

Department of Health | National Health and Medical Research Council

Naito Foundation

Leukemia Foundation of Australia SERP Grant

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0811-3.pdf

Reference56 articles.

1. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115–23.

2. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. 2011;24:203–16.

3. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–8.

4. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl J Med. 2017;377:1331–44.

5. Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34:324–56.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic crosstalk: Extracellular ATP and the tumor microenvironment in cancer progression and therapy;Cellular Signalling;2024-09

2. The battle within: cell death by phagocytosis in cancer;Clinical and Translational Oncology;2024-08-21

3. The significance of CD8+ tumor-infiltrating lymphocytes exhaustion heterogeneity and its underlying mechanism in diffuse large B-cell lymphoma;International Immunopharmacology;2024-08

4. Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy;Human Immunology;2024-05

5. Self-delivery immunological adenosine effector for photodynamic activated immunotherapy against metastatic tumors;Materials & Design;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3